1. Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells
    Peng Wang et al, 2019, Cell Metabolism CrossRef
  2. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
    D. Ciardiello et al, 2020, Annals of Oncology CrossRef
  3. TGF-β signaling networks in the tumor microenvironment
    Max Kam-Kwan Chan et al, 2022, Cancer Letters CrossRef
  4. Targeting the TGFβ pathway for cancer therapy
    Cindy Neuzillet et al, 2015, Pharmacology & Therapeutics CrossRef
  5. Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective
    David Danielpour, 2024, Pharmaceuticals CrossRef
  6. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells
    Katrin Moses et al, 2016, Seminars in Immunology CrossRef
  7. TGFβ signaling networks in ovarian cancer progression and plasticity
    Asha Kumari et al, 2021, Clinical & Experimental Metastasis CrossRef
  8. Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model
    Masaki Takahashi et al, 2022, Molecular Therapy - Nucleic Acids CrossRef
  9. Reverting Immune Suppression to Enhance Cancer Immunotherapy
    Bella S. Guerrouahen et al, 2020, Frontiers in Oncology CrossRef
  10. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy
    Xianhui Chen et al, 2021, Molecular Therapy - Oncolytics CrossRef
  11. The application of antibody-based agents in cancer therapy based on their mechanisms of action
    Kewen Qian et al, 2024, Fundamental Research CrossRef
  12. TGFβ biology in cancer progression and immunotherapy
    Rik Derynck et al, 2021, Nature Reviews Clinical Oncology CrossRef
  13. Cancer Immunology
    Diane Tseng et al, 2020, Abeloff's Clinical Oncology CrossRef
  14. Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives
    Christopher J. Hanley et al, 2021, Oncotarget CrossRef
  15. Harnessing Carcinoma Cell Plasticity Mediated by TGF-β Signaling
    Xuecong Wang et al, 2021, Cancers CrossRef
  16. Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate
    Aaron Kunamalla et al, 2016, Circulation Research CrossRef
  17. Recent progress in TGF-β inhibitors for cancer therapy
    Cheng-Yi Huang et al, 2021, Biomedicine & Pharmacotherapy CrossRef
  18. Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy
    Zhen-Hua Wu et al, 2022, Cancers CrossRef
  19. 3D Printed Scaffold Based on Type I Collagen/PLGA_TGF-β1 Nanoparticles Mimicking the Growth Factor Footprint of Human Bone Tissue
    Federica Banche-Niclot et al, 2022, Polymers CrossRef
  20. Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model
    Camila Leonel et al, 2017, Journal of Mammary Gland Biology and Neoplasia CrossRef
  21. Targeting TGF-β Signaling for Therapeutic Gain
    Rosemary J. Akhurst, 2017, Cold Spring Harbor Perspectives in Biology CrossRef
  22. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo
    Xi-Ran He et al, 2017, Journal of Ethnopharmacology CrossRef
  23. Overcoming TGFβ-mediated immune evasion in cancer
    Daniele V. F. Tauriello et al, 2022, Nature Reviews Cancer CrossRef
  24. Radiation-primed TGF-β trapping by engineered extracellular vesicles for targeted glioblastoma therapy
    Ruyu Liang et al, 2024, Journal of Controlled Release CrossRef
  25. Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
    Max Kam-Kwan Chan et al, 2023, Exploration of Targeted Anti-tumor Therapy CrossRef
  26. Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer
    Yun Xing et al, 2022, Acta Pharmacologica Sinica CrossRef
  27. Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer
    Michiko Harao et al, 2015, BioDrugs CrossRef
  28. Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
    Brian T. Welsh et al, 2021, International Journal of Toxicology CrossRef
  29. Mammary Gland Involution Provides a Unique Model to Study the TGF-β Cancer Paradox
    Qiuchen Guo et al, 2017, Journal of Clinical Medicine CrossRef
  30. Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
    Masaki Terabe et al, 2017, OncoImmunology CrossRef
  31. 68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer
    Ke Li et al, 2024, Journal of Clinical Investigation CrossRef
  32. The TGFβ and Androgen Receptor Signaling Pathways Converge to Support Anoikis Resistance in Triple Negative Breast Cancer
    Emmanuel Rosas et al, 2021, Anoikis CrossRef